These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 22219001)

  • 1. The founder Ashkenazi Jewish mutations in the MSH2 and MSH6 genes in Israeli patients with gastric and pancreatic cancer.
    Laitman Y; Herskovitz L; Golan T; Kaufman B; Paluch SS; Friedman E
    Fam Cancer; 2012 Jun; 11(2):243-7. PubMed ID: 22219001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The founder mutation MSH2*1906G-->C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population.
    Foulkes WD; Thiffault I; Gruber SB; Horwitz M; Hamel N; Lee C; Shia J; Markowitz A; Figer A; Friedman E; Farber D; Greenwood CM; Bonner JD; Nafa K; Walsh T; Marcus V; Tomsho L; Gebert J; Macrae FA; Gaff CL; Paillerets BB; Gregersen PK; Weitzel JN; Gordon PH; MacNamara E; King MC; Hampel H; De La Chapelle A; Boyd J; Offit K; Rennert G; Chong G; Ellis NA
    Am J Hum Genet; 2002 Dec; 71(6):1395-412. PubMed ID: 12454801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A636P is associated with early-onset colon cancer in Ashkenazi Jews.
    Guillem JG; Rapaport BS; Kirchhoff T; Kolachana P; Nafa K; Glogowski E; Finch R; Huang H; Foulkes WD; Markowitz A; Ellis NA; Offit K
    J Am Coll Surg; 2003 Feb; 196(2):222-5. PubMed ID: 12595050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-amplicon MSH2 A636P mutation testing in Ashkenazi Jewish patients with colorectal cancer: role in presurgical management.
    Guillem JG; Glogowski E; Moore HG; Nafa K; Markowitz AJ; Shia J; Offit K; Ellis NA
    Ann Surg; 2007 Apr; 245(4):560-5. PubMed ID: 17414604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of two Ashkenazi Jewish founder mutations in MSH6 gene causing Lynch syndrome.
    Raskin L; Schwenter F; Freytsis M; Tischkowitz M; Wong N; Chong G; Narod SA; Levine DA; Bogomolniy F; Aronson M; Thibodeau SN; Hunt KS; Rennert G; Gallinger S; Gruber SB; Foulkes WD
    Clin Genet; 2011 Jun; 79(6):512-22. PubMed ID: 21155762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The rate of the recurrent MSH6 mutations in Ashkenazi Jewish breast cancer patients.
    Bernstein-Molho R; Laitman Y; Schayek H; Iomdin S; Friedman E
    Cancer Causes Control; 2019 Jan; 30(1):97-101. PubMed ID: 30498870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Ashkenazi founder mutation in the MSH6 gene leading to HNPCC.
    Goldberg Y; Porat RM; Kedar I; Shochat C; Galinsky D; Hamburger T; Hubert A; Strul H; Kariiv R; Ben-Avi L; Savion M; Pikarsky E; Abeliovich D; Bercovich D; Lerer I; Peretz T
    Fam Cancer; 2010 Jun; 9(2):141-50. PubMed ID: 19851887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lynch Syndrome in high risk Ashkenazi Jews in Israel.
    Goldberg Y; Kedar I; Kariiv R; Halpern N; Plesser M; Hubert A; Kaduri L; Sagi M; Lerer I; Abeliovich D; Hamburger T; Nissan A; Goldshmidt H; Solar I; Geva R; Strul H; Rosner G; Baris H; Levi Z; Peretz T
    Fam Cancer; 2014 Mar; 13(1):65-73. PubMed ID: 23990280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homozygosity of MSH2 c.1906G-->C germline mutation is associated with childhood colon cancer, astrocytoma and signs of Neurofibromatosis type I.
    Toledano H; Goldberg Y; Kedar-Barnes I; Baris H; Porat RM; Shochat C; Bercovich D; Pikarsky E; Lerer I; Yaniv I; Abeliovich D; Peretz T
    Fam Cancer; 2009; 8(3):187-94. PubMed ID: 19101824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A636P testing in Ashkenazi Jews.
    Guillem JG; Moore HG; Palmer C; Glogowski E; Finch R; Nafa K; Markowitz AJ; Offit K; Ellis NA
    Fam Cancer; 2004; 3(3-4):223-7. PubMed ID: 15516845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel MSH2 germline mutation in a Druze HNPCC family.
    Zidan J; Niessen RC; Laitman Y; Rozeveld D; Hofstra RM; Friedman E
    Fam Cancer; 2008; 7(2):135-9. PubMed ID: 17661183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium.
    Plaschke J; Engel C; Krüger S; Holinski-Feder E; Pagenstecher C; Mangold E; Moeslein G; Schulmann K; Gebert J; von Knebel Doeberitz M; Rüschoff J; Loeffler M; Schackert HK
    J Clin Oncol; 2004 Nov; 22(22):4486-94. PubMed ID: 15483016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Muir-Torre Syndrome and founder mismatch repair gene mutations: A long gone historical genetic challenge.
    Ponti G; Manfredini M; Tomasi A; Pellacani G
    Gene; 2016 Sep; 589(2):127-32. PubMed ID: 26143115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MLH1 promoter germline-methylation in selected probands of Chinese hereditary non-polyposis colorectal cancer families.
    Zhou HH; Yan SY; Zhou XY; Du X; Zhang TM; Cai X; Lu YM; Cai SJ; Shi DR
    World J Gastroenterol; 2008 Dec; 14(48):7329-34. PubMed ID: 19109866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of germline genetic mutations in patients with pancreatic cancer.
    Salo-Mullen EE; O'Reilly EM; Kelsen DP; Ashraf AM; Lowery MA; Yu KH; Reidy DL; Epstein AS; Lincoln A; Saldia A; Jacobs LM; Rau-Murthy R; Zhang L; Kurtz RC; Saltz L; Offit K; Robson ME; Stadler ZK
    Cancer; 2015 Dec; 121(24):4382-8. PubMed ID: 26440929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gynecologic malignancies in Ashkenazi families with the MSH2 A636P founder mutation.
    Lavie O; Gruber SB; Lejbkowicz F; Dishon S; Rennert G
    Am J Obstet Gynecol; 2008 Aug; 199(2):148.e1-3. PubMed ID: 18674656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microsatellite instability and novel mismatch repair gene mutations in northern Chinese population with hereditary non-polyposis colorectal cancer.
    Sheng JQ; Chan TL; Chan YW; Huang JS; Chen JG; Zhang MZ; Guo XL; Mu H; Chan AS; Li SR; Yuen ST; Leung SY
    Chin J Dig Dis; 2006; 7(4):197-205. PubMed ID: 17054581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The HNPCC associated MSH2*1906G-->C founder mutation probably originated between 1440 CE and 1715 CE in the Ashkenazi Jewish population.
    Sun S; Greenwood CM; Thiffault I; Hamel N; Chong G; Foulkes WD
    J Med Genet; 2005 Oct; 42(10):766-8. PubMed ID: 16199548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High risk of colorectal and endometrial cancer in Ashkenazi families with the MSH2 A636P founder mutation.
    Mukherjee B; Rennert G; Ahn J; Dishon S; Lejbkowicz F; Rennert HS; Shiovitz S; Moreno V; Gruber SB
    Gastroenterology; 2011 Jun; 140(7):1919-26. PubMed ID: 21419771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Constitutional Mismatch Repair Deficiency in Israel: High Proportion of Founder Mutations in MMR Genes and Consanguinity.
    Baris HN; Barnes-Kedar I; Toledano H; Halpern M; Hershkovitz D; Lossos A; Lerer I; Peretz T; Kariv R; Cohen S; Half EE; Magal N; Drasinover V; Wimmer K; Goldberg Y; Bercovich D; Levi Z
    Pediatr Blood Cancer; 2016 Mar; 63(3):418-27. PubMed ID: 26544533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.